[1] Wynn TA.Cellular and molecular mechanisms of fibrosis.J Pathol,2008,214(2):199-210. [2] Gressner AM,Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med,2006,10(1):76-99. [3] Zheng Y,Collins SL,Lutz MA,et al.A role for mammalian target of rapamycin in regulating T cell activation versus anergy.J Immunol,2007,178:2163-2170. [4] Patsenker E.Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol,2011,doi:10.1016/j.jhep.2010.10.044. [5] 彭贵主,吴波,单人锋,等. mTOR/P70S6K信号通路在肝细胞肝癌中的表达及临床意义.世界华人消化杂志,2008,16(29):3279-3282. [6] 杨妙芳,许小兵,吴文娟,等. 核糖体S6激酶对肝星状细胞内胶原表达的调控. 第四军医大学学报,2008,29(19):1753-1756. [7] 车颖,徐婷婷,姜妙娜,等. 肝复康胶囊对实验性肝纤维化大鼠肝细胞的保护作用. 中药材,2004,27(6):428-429. [8] 车颖,徐婷婷,姜妙娜,等.肝复康抗大鼠肝纤维化的实验研究.中国中药杂志,2004,29(6):599-600. [9] Xu TT,Jiang MN,Li C.Effect of Chinese traditional compound, Gan-fu-kang,on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms.Hepatol Res,2007,37:221-229. [10] Lou JL,Jiang MN,Li C,et al. Herb medicine Gan-fu-kang attenuates liver injury in a rat fibrotic model. J Ethnopharmacol,2010,128:131-138. [11] 张彩华,崔晓栋,姜妙娜,等. 肝复康不同浓度含药血清对肝星状细胞Ⅰ、Ⅲ型胶原及细胞基质的影响. 中国组织工程研究与临床康复,2008,12(33):6496-6499. [12] Sonoyama T,Tamura N,Miyashita K,et al.Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide. FEBS Lett,2009,583(12):2067-2070. [13] Rao RD,Buekner JC,Sarkaria JN.Mammalian target of rapamyein(mTOR) inhibitors as anticancer agents.Curr Caneer Drug Targets,2004:4:621-635. [14] Buck M,Chojkier M A.Ribosomal S-6 Kinase-mediated signal to C/EBP-b is critical for the development of liver fibrosis.PLoS ONE,2007,2(12):e1372. [15] Jamison JT,Kayali F,Rudolph J,et al.Persistent redistribution of poly- adenylated mRNAs correlates with translation arrest and cell death following global brain ischemia and reperfusion.Neuroseience,2008,154:504-520. |